Shattuck Labs, Inc. (STTK) earnings date
Mar 4, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 27% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-18
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 40 days, typically, give or take 19 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 5, 2026 | before open | 36 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Thu, May 7, 2026 | before open | 37 | 8-K |
| Q4 FY2025 | Thu, Mar 5, 2026 | before open | 64 | 8-K |
| Q3 FY2025 | Thu, Nov 6, 2025 | after close | 37 | 8-K |
| Q2 FY2025 | Thu, Aug 14, 2025 | before open | 45 | 8-K |
| Q1 FY2025 | Thu, May 1, 2025 | after close | 31 | 8-K |
| Q4 FY2024 | Thu, Mar 27, 2025 | before open | 86 | 8-K |
What they guided beta
| Q3 FY2026 | "Document Exhibit 99.1 Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights – Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial initiation expected in the fourth quarter of 2026 – – Presented preclinical data for SL-846 at UEG Week 2026, including data from a chronic toxicology study in non-human primates – AUSTIN, TX and DURHAM, NC, Nov. 05, 2026 -- Shattuck Labs, Inc. (Shat" exhibit |
| Q3 FY2026 | ""In addition, SL-846 has demonstrated a compelling profile in preclinical studies, and we expect to share initial Phase 1 clinical data for what we expect to be a first-in-class DR3 by IL-23 receptor blocking antibody in 2027." DR3 Program Development in 2026 Shattuck is advancing a pipeline of DR3-targeted monoclonal and bispecific antibody product candidates for the treatment of inflammatory and immune-mediated diseases." exhibit |
| Q3 FY2026 | "These data are expected in the first half of 2028." exhibit |
| Q3 FY2026 | "Announced plans to initiate the RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in patients with moderate to severe hidradenitis suppurativa, with trial initiation expected in the fourth quarter of 2026." exhibit |
| Q3 FY2026 | "Primary endpoint is HiSCR50 response at Week 16, with data expected in the first half of 2028." exhibit |
| Q2 FY2026 | "Document Exhibit 99.1 Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights – Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling prolonged dosing intervals – – RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with Crohn’s disease expected to initiate in the third quarter of 2026 – – Announced lead DR3 x IL-23 receptor blocking, half-life extended bispecific antibody product candidate, SL-846, with " exhibit |
| Q2 FY2026 | ""The RECEPTIVE-CD1 Phase 2b clinical trial in Crohn’s disease is on track to initiate in the third quarter, and is designed to establish the efficacy profile of SL-325 across three dose levels, both at induction and at maintenance time points." exhibit |
| Q2 FY2026 | "RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease is expected to initiate in the third quarter of 2026." exhibit |
| Q2 FY2026 | "These data are expected in the first half of 2028." exhibit |
| Q2 FY2026 | "Preclinical data for SL-846, including safety, pharmacokinetics, and receptor occupancy from the ongoing GLP toxicology study are expected to be presented in a poster at UEG Week, to be held October 17-20, 2026." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/STTK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/STTK
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/STTK/"><img src="https://veritasdata.dev/embed/STTK.svg" alt="STTK earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/STTK/)
Script
<script async src="https://veritasdata.dev/embed/STTK.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/STTK"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.